Cytokinetics Announces Executive and Board Changes
Ticker: CYTK · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $50,000, $7,500, $440,000, $700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, personnel
Related Tickers: CYTK
TL;DR
Cytokinetics shakes up leadership: Dr. Malik is new CMO, Lori Wood joins board.
AI Summary
Cytokinetics, Inc. announced on August 19, 2025, changes in its executive team and board of directors. Specifically, Dr. Fady Malik has been appointed as the Chief Medical Officer, and Ms. Lori Wood has joined as a new member of the Board of Directors. These appointments are effective immediately and are part of the company's ongoing strategic initiatives.
Why It Matters
These leadership changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Cytokinetics, Inc. (company) — Registrant
- Dr. Fady Malik (person) — Appointed Chief Medical Officer
- Ms. Lori Wood (person) — Appointed to Board of Directors
- August 19, 2025 (date) — Effective date of changes
FAQ
What are the specific responsibilities of Dr. Fady Malik as the new Chief Medical Officer?
The filing states Dr. Fady Malik has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond this title.
What is Ms. Lori Wood's background and experience that led to her appointment to the Board of Directors?
The filing announces Ms. Lori Wood's appointment to the Board of Directors but does not provide details on her background or experience.
Are there any other executive or board changes occurring concurrently with these appointments?
The filing specifically mentions the appointment of Dr. Fady Malik and Ms. Lori Wood, but does not indicate any other concurrent changes.
What is the strategic rationale behind these leadership changes at Cytokinetics?
The filing states these changes are effective immediately and are part of the company's ongoing strategic initiatives, but does not elaborate on the specific rationale.
When are these appointments officially effective?
The appointments of Dr. Fady Malik and Ms. Lori Wood are effective as of August 19, 2025.
Filing Stats: 814 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2025-08-20 07:57:51
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
- $50,000 — comprised of: (i) an annual retainer of $50,000 for his service on the Board commencing
- $7,500 — of service, (ii) an annual retainer of $7,500 for his service on the Board's Complian
- $440,000 — h an aggregate grant date fair value of $440,000, the stock options of which will vest m
- $700,000 — options with a grant date fair value of $700,000. The Initial Grant will vest monthly ov
Filing Documents
- cytk-20250819.htm (8-K) — 43KB
- 0000950170-25-110368.txt ( ) — 143KB
- cytk-20250819.xsd (EX-101.SCH) — 23KB
- cytk-20250819_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: August 20, 2025 By: /s/ John Faurescu John Faurescu SVP, Deputy General Counsel & Secretary